Intravenous Levodopa for the Diagnosis of Parkinson's Disease
NCT00001928 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25
Last updated 2008-03-04
Summary
Patients with Parkinson's disease have low levels of the neurotransmitter dopamine. Dopamine is responsible for motor function and normal physical activity. Patients with Parkinson's disease typically suffer from tremors, rigid muscles, stooped postures, and walk with a shuffle. The drug levodopa acts as a replacement for dopamine and has been has been used effectively for over 30 years as treatment for Parkinsons disease. Because of its effectiveness, levodopa has been used to distinguish Parkinson's disease from other conditions that may resemble Parkinson's disease.
Traditionally, levodopa has been given as a pill. In this study, researchers would like to inject levodopa directly into a vein (intravenous) in order to diagnose cases of Parkinson's disease. This method provides immediate results and allows doctors to adjust the dose of levodopa very carefully. Because the intravenous method of giving levodopa is less practical than oral medication, it is not an available alternative for the routine treatment of Parkinson's disease. However, it may be useful for faster diagnosis of the disease and for determining effective doses of oral medication.
Conditions
- Parkinson Disease
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-03-31
- Completion
- 2000-07-31
Countries
- United States
Study Locations
More Related Trials
-
ACP-103 to Treat Parkinson's Disease
NCT00086294 ·Status: COMPLETED ·Phase: PHASE2
-
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
NCT00203034 ·Status: COMPLETED ·Phase: PHASE3
-
Lisuride Patch to Treat Parkinson's Disease
NCT00089622 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
NCT00099268 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
NCT00219284 ·Status: COMPLETED ·Phase: PHASE4
-
Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease
NCT00914134 ·Status: COMPLETED ·Phase: PHASE4
-
Study of LY300164 for the Treatment of Parkinson's Disease
NCT00004576 ·Status: COMPLETED ·Phase: PHASE2
-
JP-1730 to Treat Parkinson's Disease
NCT00040209 ·Status: COMPLETED ·Phase: PHASE2
-
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
NCT00642356 ·Status: TERMINATED ·Phase: PHASE4
-
Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
NCT00467597 ·Status: COMPLETED
-
Treatment of Parkinson's Disease With Eliprodil
NCT00001929 ·Status: COMPLETED ·Phase: PHASE2
-
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
NCT00888186 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease
NCT04952194 ·Status: UNKNOWN ·Phase: PHASE4
-
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
NCT02577523 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease
NCT00032812 ·Status: COMPLETED
-
Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease
NCT00921128 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
NCT00660387 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
NCT01725802 ·Status: COMPLETED ·Phase: PHASE1
-
KW-6002 to Treat Parkinson's Disease
NCT00006337 ·Status: COMPLETED ·Phase: PHASE2
-
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
NCT05083260 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
NCT02486432 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
NCT01486628 ·Status: COMPLETED ·Phase: PHASE1
-
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
NCT01049984 ·Status: COMPLETED ·Phase: PHASE4
-
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
NCT01227265 ·Status: COMPLETED ·Phase: PHASE3
-
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
NCT00160576 ·Status: COMPLETED ·Phase: PHASE2